Prestige Biologics프레스티지바이오로직스
334970 · KOSDAQ · ₩334970 · 프레스티지바이오로직스
₩1,158▼ ₩35 (2.93%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩13B | ₩2.2B | ₩1.7B | ₩16M | ₩3.2B |
| Cost of sales | ₩28B | ₩11B | ₩1.2B | ₩12M | ₩873M |
| Gross profit | −₩16B | −₩8.7B | ₩518M | ₩3.6M | ₩2.4B |
| Operating income | −₩34B | −₩33B | −₩22B | −₩37B | −₩27B |
| Net income | −₩27B | −₩29B | −₩18B | −₩50B | −₩39B |
| Net income to shareholders | −₩27B | −₩29B | −₩18B | −₩50B | −₩39B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩270B | ₩289B | ₩306B | ₩258B | ₩207B |
| Current assets | ₩41B | ₩56B | ₩70B | ₩30B | ₩55B |
| Cash and equivalents | ₩1.6B | ₩30B | ₩45B | ₩15B | ₩37B |
| Total liabilities | ₩135B | ₩218B | ₩206B | ₩140B | ₩100B |
| Current liabilities | ₩102B | ₩92B | ₩89B | ₩33B | ₩28B |
| Borrowings | ₩91B | ₩173B | ₩160B | ₩119B | ₩78B |
| Total equity | ₩135B | ₩72B | ₩100B | ₩118B | ₩107B |
| Shareholders' equity | ₩135B | ₩72B | ₩100B | ₩118B | ₩107B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩18B | −₩8.3B | −₩4.4B | −₩34B | −₩26B |
| Capital spending | ₩5.2B | ₩8.5B | ₩19B | ₩85B | — |
| Free cash flow | −₩24B | −₩17B | −₩24B | −₩119B | −₩26B |
Consolidated where available. Amounts in won.
Also known as: Prestige Biologics / 프레스티지바이오로직스 / 334970 / KRX:334970
Source: KRX statistical information